Literature DB >> 3774212

Muscarinic receptor subtypes in hippocampus in Alzheimer's disease and mixed dementia type.

A Nordberg, I Alafuzoff, B Winblad.   

Abstract

The relative proportion of super-high, high and low affinity agonist binding sites was measured in the hippocampus from individuals with dementia of the Alzheimer type (AD/SDAT), mixed (AD-MID) type and controls, using labelled quinuclidinyl benzilate ([3H]QNB) competing with unlabelled carbachol. A significant reduced number of [3H]QNB binding sites was obtained in dementia groups. A significant decrease in the proportion of super-high affinity agonist (V1) binding sites was found in the AD-MID group compared to controls while no change was found in the AD/SDAT group. The affinity constant (K1) for the V1 site was also significantly lower in the AD-MID group compared to controls.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3774212     DOI： 10.1016/0304-3940(86)90456-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  8 in total

1.  Alterations in neocortical expression of nicotinic acetylcholine receptor mRNAs following unilateral lesions of the rat nucleus basalis magnocellularis.

Authors:  I Miyai; S Ueno; S Yorifuji; H Fujimura; S Tarui
Journal:  J Neural Transm Gen Sect       Date:  1990

2.  Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia.

Authors:  E D London; M J Ball; S B Waller
Journal:  Neurochem Res       Date:  1989-08       Impact factor: 3.996

3.  Do tetrahydroaminoacridine (THA) and physostigmine restore acetylcholine release in Alzheimer brains via nicotinic receptors?

Authors:  L Nilsson; A Adem; J Hardy; B Winblad; A Nordberg
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

4.  Increased CSF HVA response to arecoline challenge in Alzheimer's disease.

Authors:  N Pomara; M Stanley; P A LeWitt; M Galloway; R Singh; D Deptula
Journal:  J Neural Transm Gen Sect       Date:  1992

5.  Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study.

Authors:  T Sunderland; G Esposito; S E Molchan; R Coppola; D W Jones; J Gorey; J T Little; M Bahro; D R Weinberger
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

6.  Cholinergic topography in Alzheimer brains: a comparison with changes in the monoaminergic profile.

Authors:  A Nordberg; P Nyberg; R Adolfsson; B Winblad
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

7.  Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease.

Authors:  Elizabeth Scarr; Catriona McLean; Brian Dean
Journal:  J Neural Transm (Vienna)       Date:  2016-09-29       Impact factor: 3.575

8.  Regulatory changes in presynaptic cholinergic function assessed in rapid autopsy material from patients with Alzheimer disease: implications for etiology and therapy.

Authors:  T A Slotkin; F J Seidler; B J Crain; J M Bell; G Bissette; C B Nemeroff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.